Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris

Inclusion Criteria: * Written informed consent must be obtained before any assessment is performed. * Female and male patients ≥ 18 years of age. * Subjects must have a diagnosis of PRP type 1, 2. * Biopsy result consistent with PRP and not diagnostic for another disease. * Moderate to severe disease defined as Psoriasis Area and Severity Index (PASI) ≥ 10. * Candidates for systemic therapy. * Inadequate response to or not suitable for topical therapy in the opinion of the investigator. * If using any of the allowed topical treatments on the affected areas, the dose and application frequency should remain stable for 2 weeks prior to randomization and until Week 24. Exclusion Criteria: * On excluded therapies, not on a stable dose of a therapy, or incompletely washed out for a therapy (Table-1.). * Previous use of a TYK2 inhibitor/enrollment in TYK2 inhibitor trials. * Known hypersensitivity or other adverse reaction to Deucravacitinib (BMS-986165). * HIV related PRP (PRP type 6). * atypical forms of PRP, e.g. presenting with ichtyosiform dermatitis, coarse palmoplantar keratosis. * Currently enrolled in any other clinical trial involving any investigational agent or device. * Presence of any other skin condition that may affect the evaluations of the study disease. * Current, severe, progressive or uncontrolled diseases that render the patient unsuitable for the trial, including any medical or psychiatric condition that, in the Investigator's opinion, would preclude the pa…